Gadobutrol (Gadavist, Gadovist, BAY86-4875) + Gadoteridol (ProHance)
Phase 3Completed 0 watching 0 views this week📈 Rising
74
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Diagnostic Imaging
Conditions
Diagnostic Imaging, Central Nervous System Diseases
Trial Timeline
Jun 1, 2008 → Apr 1, 2009
NCT ID
NCT00709852About Gadobutrol (Gadavist, Gadovist, BAY86-4875) + Gadoteridol (ProHance)
Gadobutrol (Gadavist, Gadovist, BAY86-4875) + Gadoteridol (ProHance) is a phase 3 stage product being developed by Bayer for Diagnostic Imaging. The current trial status is completed. This product is registered under clinical trial identifier NCT00709852. Target conditions include Diagnostic Imaging, Central Nervous System Diseases.
Hype Score Breakdown
Clinical
27
Activity
18
Company
7
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00709852 | Phase 3 | Completed |
Competing Products
11 competing products in Diagnostic Imaging
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Intralipid + ICI35,868 (Diprivan) + ICI35,868 (Diprivan) + EES0000645/A (SDS) | Johnson & Johnson | Phase 3 | 77 |
| Remimazolam Tosilate for Injection + Remimazolam Tosilate for Injection | Jiangsu Hengrui Medicine | Approved | 85 |
| Iopromide (Ultravist, BAY86-4877) | Bayer | Pre-clinical | 20 |
| BAY86-4367 + BAY86-4367 | Bayer | Phase 1 | 30 |
| F-18 DPA-714 (BAY85-8102) + F-18 DPA-714 (BAY85-8102) + F-18 DPA-714 (BAY85-8102) | Bayer | Phase 1 | 30 |
| Ultravist (Iopromide, BAY86-4877) | Bayer | Pre-clinical | 20 |
| Gadopentetate dimeglumine (Magnevist, BAY86-4882) | Bayer | Pre-clinical | 20 |
| Gadoxetic Acid Disodium (Primovist, BAY86-4873) | Bayer | Pre-clinical | 20 |
| Xenetix + Visipaque | Guerbet | Approved | 77 |
| Iobitridol | Guerbet | Approved | 77 |
| Dotarem (gadoterate meglumine) + Magnevist (gadopentetate dimeglumine) | Guerbet | Phase 3 | 69 |